---
title: "Autoimmune Skin Diseases"
order: 6
category: "Dermatology"
---

# Autoimmune Skin Diseases

## Overview

Autoimmune skin diseases represent a heterogeneous group of disorders characterized by immune system dysregulation leading to antibody or T-cell-mediated damage to skin structures. These conditions range from organ-specific diseases affecting only the skin to systemic autoimmune diseases with cutaneous manifestations. This chapter focuses on autoimmune blistering diseases, particularly pemphigus and bullous pemphigoid, which are prototypical examples of antibody-mediated skin diseases.

### Classification of Autoimmune Blistering Diseases

**Intraepidermal (Pemphigus Group):**
- Pemphigus vulgaris
- Pemphigus foliaceus
- Paraneoplastic pemphigus

**Subepidermal (Pemphigoid Group):**
- Bullous pemphigoid
- Mucous membrane pemphigoid (cicatricial pemphigoid)
- Pemphigoid gestationis
- Linear IgA disease
- Epidermolysis bullosa acquisita
- Dermatitis herpetiformis

### Epidemiology
- **Incidence**: Rare diseases, 1-5 per million per year
- **Demographics**: Vary by specific disease
- **Genetics**: HLA associations in many types
- **Geographic variation**: Some types more common in certain populations
- **Age**: Most common in middle-aged to elderly

### Pathophysiology Overview
- **Autoantibodies**: Directed against structural proteins in skin
- **Target antigens**: Desmosomal proteins (pemphigus), basement membrane zone proteins (pemphigoid)
- **Blister formation**: Loss of cell-cell or cell-matrix adhesion
- **Complement activation**: Contributes to inflammation and tissue damage

## Diagnostic Approach to Blistering Diseases

### Clinical Evaluation

#### History
- **Onset**: Acute vs gradual
- **Distribution**: Localized vs generalized
- **Mucosal involvement**: Oral, genital, ocular
- **Associated symptoms**: Pruritus, pain, burning
- **Medications**: Drug-induced pemphigoid possible
- **Systemic symptoms**: Malignancy association (paraneoplastic pemphigus)

#### Physical Examination
- **Blister characteristics**:
  - Size: Small vesicles vs large bullae
  - Fluid: Clear, hemorrhagic, purulent
  - Roof: Tense (intact) vs flaccid (fragile)
  - Base: Erythematous, normal, denuded
- **Distribution**: Pattern and sites
- **Nikolsky sign**: Lateral pressure causes epidermis to slide (positive in pemphigus)
- **Mucous membranes**: Oral, conjunctival, genital examination

### Diagnostic Testing

#### Skin Biopsy
- **Lesional biopsy**: Fresh intact blister
  - Formalin-fixed, routine histology
  - Shows level of split (intraepidermal vs subepidermal)
  - Inflammatory pattern
- **Special techniques**: Best diagnostic yield if both performed

#### Direct Immunofluorescence (DIF)
- **Perilesional skin**: Normal-appearing skin adjacent to blister
- **Transport**: Michel's medium or fresh to lab immediately
- **Detection**: Antibodies and complement deposited in skin
- **Patterns**:
  - **Pemphigus**: Intercellular (fishnet pattern)
  - **Bullous pemphigoid**: Linear band at basement membrane zone
  - **Dermatitis herpetiformis**: Granular deposits at dermal papillae

#### Indirect Immunofluorescence (IIF)
- **Serum**: Patient's serum on normal skin substrate
- **Detection**: Circulating autoantibodies
- **Titer**: May correlate with disease activity
- **Substrate**: Monkey esophagus (pemphigus), salt-split skin (pemphigoid)

#### ELISA
- **Enzyme-linked immunosorbent assay**: Detects specific autoantibodies
- **Antigens**: Desmoglein 1 and 3 (pemphigus), BP180, BP230 (bullous pemphigoid)
- **Advantages**: Quantitative, correlates with disease activity
- **Monitoring**: Useful for treatment response

## Pemphigus

### Overview
Pemphigus is a group of rare, chronic, autoimmune blistering diseases characterized by intraepidermal blister formation due to loss of keratinocyte cell-cell adhesion (acantholysis). The term "pemphigus" derives from the Greek word for "blister."

### Pathophysiology

#### Autoantibodies
- **Target antigens**: Desmogleins (desmosomal cadherins)
  - **Desmoglein 3 (Dsg3)**: 130 kDa, predominant in mucous membranes
  - **Desmoglein 1 (Dsg1)**: 160 kDa, predominant in superficial epidermis
- **IgG antibodies**: Mostly IgG4 subclass
- **Mechanism**: Antibody binding → loss of cell adhesion (acantholysis) → blister formation
- **Complement**: Not required for acantholysis (antibody binding sufficient)

#### Desmoglein Compensation Theory
- **Mucosal-dominant pemphigus vulgaris**: Anti-Dsg3 only
  - Oral lesions: Dsg3 predominant, no compensation by Dsg1
  - Skin intact: Dsg1 compensates for loss of Dsg3 function
- **Mucocutaneous pemphigus vulgaris**: Anti-Dsg3 and anti-Dsg1
  - Oral and skin lesions: Neither desmoglein can compensate
- **Pemphigus foliaceus**: Anti-Dsg1 only
  - Skin lesions (superficial): Dsg1 predominant
  - Mucous membranes intact: Dsg3 compensates

### Pemphigus Vulgaris (PV)

#### Epidemiology
- **Most common type**: 70% of pemphigus cases
- **Incidence**: 0.5-3.2 per million per year
- **Age**: 40-60 years (median 50-60)
- **Gender**: Slight female predominance
- **Ethnicity**: More common in Ashkenazi Jews, Mediterranean, Middle Eastern populations
- **HLA association**: HLA-DRB1*0402, DQB1*0503

#### Clinical Presentation

**Mucosal Involvement (Initial Presentation in 50-70%):**
- **Oral mucosa** (90% eventually affected):
  - Painful erosions and ulcers
  - Buccal mucosa, palate, gingiva, tongue, lips
  - Intact bullae rare (rupture quickly)
  - Eating and drinking painful
  - May be only site for months before skin involvement
- **Other mucosae**:
  - Pharynx, larynx, esophagus (dysphagia, odynophagia)
  - Conjunctivae (rare but can cause scarring)
  - Nasal mucosa (crusting, epistaxis)
  - Genital mucosa (painful erosions)

**Cutaneous Involvement:**
- **Morphology**:
  - Flaccid bullae arising on normal or erythematous skin
  - Fragile, rupture easily → erosions and crusts
  - Erosions more common than intact bullae
- **Distribution**:
  - Scalp, face, chest, back, axillae, groin
  - Pressure points common
- **Nikolsky sign**: Positive (pathognomonic but not sensitive)
  - Lateral pressure on perilesional skin → epidermis slides off
- **Healing**: Without scarring (intraepidermal), but post-inflammatory pigmentation
- **Pruritus**: Usually absent or mild
- **Pain**: Erosions can be very painful

**Clinical Variants:**
- **Mucosal-dominant**: Oral lesions only or predominant
- **Mucocutaneous**: Both oral and skin involvement
- **Cutaneous**: Skin lesions without mucosal (rare)

#### Diagnosis

**Histopathology:**
- **Suprabasal acantholysis**: Cleft above basal layer
- **"Row of tombstones"**: Basal cells remain attached to basement membrane
- **Acantholytic cells**: Rounded keratinocytes in blister cavity
- **Eosinophils**: Often present in blister and dermis

**Direct Immunofluorescence:**
- **Pattern**: Intercellular IgG and C3 ("fishnet" or "chicken-wire" pattern)
- **Location**: Throughout epidermis
- **Sensitivity**: >90%

**Indirect Immunofluorescence:**
- **Monkey esophagus substrate**: Intercellular pattern
- **Titer**: Present in most patients, correlates with disease activity
- **Specificity**: High for pemphigus

**ELISA:**
- **Anti-Dsg3**: Present in all PV patients
- **Anti-Dsg1**: Present in mucocutaneous PV
- **Quantitative**: Levels correlate with disease activity
- **Monitoring**: Useful for assessing treatment response

#### Differential Diagnosis
- **Bullous pemphigoid**: Tense bullae, elderly, subepidermal split
- **Mucous membrane pemphigoid**: Subepidermal, scarring
- **Paraneoplastic pemphigus**: Polymorphic, severe mucositis, malignancy
- **Erythema multiforme**: Targetoid lesions, often viral trigger
- **Stevens-Johnson syndrome**: Drug-induced, severe systemic symptoms
- **Herpetic gingivostomatitis**: Acute, viral culture positive
- **Aphthous stomatitis**: Recurrent, no skin lesions, no acantholysis

#### Treatment

**Initial Treatment (Moderate to Severe):**

*Systemic Corticosteroids (First-line):*
- **Prednisone**: 0.5-1.5 mg/kg/day (typically 60-80 mg/day)
- **Goal**: Control new blister formation and erosion healing
- **Duration**: Continue high dose until no new lesions for 2 weeks
- **Taper**: Slow taper over months (10-20% reduction every 1-2 weeks)
  - Too rapid taper → relapse
  - Goal: Maintain remission on <10 mg/day or off

*Steroid-Sparing Agents (Add Early):*
- **Rationale**: Reduce corticosteroid dose and side effects
- **Initiate**: Simultaneously with or shortly after corticosteroids

**Options:**

*Azathioprine:*
- **Dose**: 1-3 mg/kg/day (typically 100-200 mg/day)
- **Mechanism**: Purine synthesis inhibition
- **Onset**: 6-12 weeks for full effect
- **Monitoring**: CBC every 1-2 weeks initially, then monthly
- **Screening**: TPMT activity (increased toxicity if deficient)
- **Side effects**: Bone marrow suppression, hepatotoxicity, GI upset, increased infection risk

*Mycophenolate Mofetil:*
- **Dose**: 2-3 g/day divided twice daily
- **Mechanism**: Inosine monophosphate dehydrogenase inhibitor
- **Onset**: 8-12 weeks
- **Monitoring**: CBC monthly
- **Side effects**: GI upset, bone marrow suppression
- **Advantage**: May work faster than azathioprine

*Rituximab:*
- **Indication**: Moderate to severe PV, increasingly used first-line
- **Mechanism**: Anti-CD20 monoclonal antibody → B-cell depletion
- **Dosing regimens**:
  - Lymphoma protocol: 375 mg/m² IV weekly × 4 doses
  - Rheumatoid arthritis protocol: 1000 mg IV on days 1 and 15
  - Repeated cycles every 4-6 months or as needed
- **Efficacy**: 80-90% complete remission
- **Advantages**: High efficacy, durable remission, steroid-sparing
- **Monitoring**: CBC, immunoglobulins, hepatitis B screening
- **Side effects**: Infusion reactions, infection risk, hypogammaglobulinemia
- **Premedication**: Acetaminophen, antihistamine, corticosteroid
- **Emerging**: May become first-line therapy

*IVIG (Intravenous Immunoglobulin):*
- **Dose**: 2 g/kg per cycle, given over 2-5 days
- **Frequency**: Monthly initially, can space out
- **Mechanism**: Multiple (Fc receptor blockade, anti-idiotype antibodies, complement inhibition)
- **Efficacy**: Adjunctive or monotherapy in refractory cases
- **Side effects**: Headache, aseptic meningitis, thrombosis, renal dysfunction
- **Cost**: Very expensive

*Other Agents (Less Commonly Used):*
- **Methotrexate**: 10-25 mg weekly
- **Cyclophosphamide**: Severe refractory disease (significant toxicity)
- **Cyclosporine**: 3-5 mg/kg/day
- **Dapsone**: Adjunctive, limited efficacy in pemphigus
- **Gold**: Historical, rarely used now
- **Immunoadsorption/Plasmapheresis**: Acute severe disease, remove circulating antibodies

**Adjunctive and Supportive Care:**
- **Wound care**:
  - Gentle cleansing
  - Non-adherent dressings
  - Petroleum-based ointments
- **Pain control**: Oral analgesics, topical anesthetics (lidocaine rinses)
- **Oral care**:
  - Soft diet, avoid spicy/acidic foods
  - Salt water rinses
  - Viscous lidocaine before meals
  - Magic mouthwash (diphenhydramine, viscous lidocaine, antacid)
- **Infection prevention**:
  - Monitor for secondary infection
  - Antibiotics if infected
- **Bone protection**: Calcium, vitamin D, consider bisphosphonate with chronic steroids
- **PCP prophylaxis**: If on high-dose corticosteroids + other immunosuppression (TMP-SMX)

**Mild/Localized Disease:**
- **Topical/intralesional corticosteroids**: Very limited disease
- **Dapsone**: May be sufficient for some cases
- **Tetracycline + nicotinamide**: Case reports, limited evidence

#### Disease Monitoring
- **Clinical assessment**: Frequency of new lesions, healing of erosions
- **ELISA**: Dsg1 and Dsg3 antibody levels
  - Correlate with disease activity
  - Useful for monitoring treatment response
  - Increasing titers may predict relapse
- **Laboratory**: CBC, metabolic panel, glucose (steroid side effects)

#### Prognosis
- **Without treatment**: Mortality >90% (infection, sepsis)
- **With treatment**: Mortality <10%
- **Causes of death**: Infection (most common), steroid complications
- **Remission**: 50-75% achieve complete remission off therapy
  - May take years
  - Relapse common during taper
- **Chronic disease**: Some require long-term low-dose therapy
- **Worse prognosis**: Elderly, extensive disease at presentation, comorbidities

### Pemphigus Foliaceus (PF)

#### Epidemiology
- **Less common**: Than pemphigus vulgaris
- **Age**: Similar to PV (middle-aged to elderly)
- **Endemic form**: Fogo selvagem in rural Brazil (environmental trigger suspected)
- **HLA association**: HLA-DRB1*0404

#### Pathophysiology
- **Autoantibodies**: Anti-desmoglein 1 only
- **Acantholysis**: Superficial (granular layer)
- **Mucous membranes spared**: Desmoglein 3 provides compensation

#### Clinical Presentation
- **Skin only**: No mucosal involvement (key distinction from PV)
- **Morphology**:
  - Superficial erosions and crusts (bullae rupture quickly)
  - Scales (superficial blistering)
  - Erythematous base
- **Distribution**:
  - Seborrheic areas: Face, scalp, chest, back
  - May generalize (exfoliative erythroderma)
- **Pruritus**: More common than in PV
- **Nikolsky sign**: May be positive

#### Diagnosis
- **Histopathology**: Subcorneal or superficial acantholysis
- **DIF**: Intercellular IgG and C3 (like PV)
- **IIF**: Intercellular pattern on monkey esophagus
- **ELISA**: Anti-Dsg1 positive, anti-Dsg3 negative

#### Differential Diagnosis
- **Seborrheic dermatitis**: No acantholysis
- **Impetigo**: Bacterial culture positive
- **Subacute cutaneous lupus**: ANA positive, different histology
- **Dermatitis (eczema)**: Spongiosis, no acantholysis

#### Treatment
- **Similar to PV**: Systemic corticosteroids + steroid-sparing agents
- **Generally milder**: May respond to lower doses
- **Dapsone**: May be more effective in PF than PV
- **Prognosis**: Better than PV (no mucosal involvement, less morbidity)

### Paraneoplastic Pemphigus (PNP)

#### Overview
- **Rarest form**: Of pemphigus
- **Associated with malignancy**: Underlying neoplasm in all cases
- **Severe disease**: Worst prognosis of pemphigus variants
- **Mortality**: 75-90% (malignancy, bronchiolitis obliterans)

#### Pathophysiology
- **Multiple autoantibodies**: Against various plakin proteins
  - Desmoplakin I and II
  - Envoplakin
  - Periplakin
  - BPAG1 (BP230)
  - Plectin
  - Desmoglein 3, 1
- **Trigger**: Tumor-associated immune dysregulation

#### Associated Malignancies
- **Lymphoproliferative** (most common, 75%):
  - Non-Hodgkin lymphoma
  - Chronic lymphocytic leukemia
  - Castleman disease
- **Carcinomas**: Lung, breast, colon
- **Sarcomas**: Rare
- **Thymoma**

#### Clinical Presentation
- **Severe stomatitis**:
  - Painful, refractory oral erosions
  - May involve entire oral cavity, pharynx, esophagus
  - Often first manifestation
- **Cutaneous lesions (polymorphic)**:
  - Flaccid bullae (pemphigus-like)
  - Tense bullae (pemphigoid-like)
  - Targetoid lesions (erythema multiforme-like)
  - Erythematous macules and papules
  - Lichenoid eruption
- **Conjunctival involvement**: Cicatricial changes, synechiae
- **Respiratory involvement**:
  - Bronchiolitis obliterans (life-threatening)
  - Progressive dyspnea, respiratory failure

#### Diagnosis
- **Clinical suspicion**: Severe mucositis + search for malignancy
- **Histopathology**: Variable (acantholysis, lichenoid interface, dyskeratotic keratinocytes)
- **DIF**: Intercellular IgG + basement membrane zone IgG
- **IIF**: Rat bladder epithelium substrate (specific for PNP)
- **Immunoprecipitation/immunoblot**: Detect antibodies to plakin proteins
- **Malignancy workup**: CT chest/abdomen/pelvis, PET scan, bone marrow biopsy if hematologic suspected

#### Treatment
- **Treat underlying malignancy**: Tumor resection or chemotherapy
  - Some cases improve after tumor treatment
- **Immunosuppression**:
  - High-dose corticosteroids
  - Rituximab
  - Other agents as for PV
- **Limited efficacy**: Often refractory to treatment
- **Supportive care**: Critical for mucositis, bronchiolitis

#### Prognosis
- **Poor**: Mortality 75-90%
- **Causes of death**: Malignancy, bronchiolitis obliterans, sepsis
- **Bronchiolitis obliterans**: No effective treatment, progressive
- **Best outcomes**: Benign tumors (Castleman disease) if resectable

## Bullous Pemphigoid (BP)

### Overview
Bullous pemphigoid is the most common autoimmune blistering disease. It is a subepidermal blistering disorder primarily affecting the elderly, characterized by tense bullae on an urticarial base. The disease is typically self-limited over months to years.

### Epidemiology
- **Incidence**: 7-43 per million per year (increasing)
- **Age**: Predominantly >60 years (mean 75-80 years)
- **Gender**: Slight male predominance
- **Rare in children**: Childhood BP is distinct variant
- **Increasing incidence**: Attributed to aging population and increased recognition

### Pathophysiology

#### Autoantibodies
- **Target antigens**: Hemidesmosomal proteins
  - **BP180 (BPAG2, type XVII collagen)**: 180 kDa, transmembrane
  - **BP230 (BPAG1)**: 230 kDa, intracellular
- **Most pathogenic**: Anti-BP180 antibodies
- **Mechanism**:
  - Antibody binding to BP180 NC16A domain
  - Complement activation (C3, C5)
  - Inflammatory cell recruitment (eosinophils, neutrophils)
  - Protease release
  - Basement membrane zone separation → blister

#### Triggers
- **Idiopathic**: Most cases
- **Drugs**: Furosemide, spironolactone, captopril, penicillamine, penicillin
- **Physical factors**: UV radiation, radiation therapy, burns, trauma
- **Neurologic disease**: Stroke, dementia, Parkinson disease (association observed)

### Clinical Presentation

#### Prodromal Phase (Weeks to Months)
- **Pruritus**: Intense, often precedes blisters
- **Urticarial plaques**: Erythematous, edematous plaques
- **Excoriations**: From scratching
- **No blisters yet**: May delay diagnosis
- **May be mistaken for**: Eczema, urticaria, drug eruption

#### Bullous Phase
- **Tense bullae** (hallmark):
  - Large (1-3 cm), dome-shaped
  - Fluid: Clear or hemorrhagic
  - Intact (tense roof vs flaccid in pemphigus)
  - Arise on urticarial plaques or normal skin
- **Distribution**:
  - Flexural areas: Axillae, groin, inner thighs
  - Trunk, extremities (especially lower)
  - Abdomen
  - May be localized or generalized
- **Pruritus**: Intense, severe
- **Mucosal involvement**: 10-30%
  - Oral most common (less severe than pemphigus)
  - Conjunctival rare
- **Nikolsky sign**: Negative
- **Healing**: Without scarring (occasionally milia)

#### Clinical Variants
- **Urticarial BP**: Urticarial plaques without blisters (prebullous)
- **Dyshidrosiform BP**: Vesicles on palms and soles
- **Nodular BP**: Prurigo nodularis-like lesions
- **Vegetating BP**: Vegetative plaques in flexures
- **Localized BP**: Limited to one area (often lower legs)

### Diagnosis

#### Histopathology
- **Subepidermal blister**: Clean separation at dermal-epidermal junction
- **Inflammatory infiltrate**: Eosinophils prominent in dermis and blister cavity
- **Eosinophil-rich**: Characteristic (but not specific)
- **Roof**: Contains full-thickness epidermis

#### Direct Immunofluorescence
- **Pattern**: Linear IgG and C3 at basement membrane zone
- **Sensitivity**: >90%
- **Specificity**: High for pemphigoid group

#### Indirect Immunofluorescence
- **Salt-split skin**: Demonstrates antibody binding to epidermal (roof) side
  - BP: Epidermal (roof) binding
  - EBA: Dermal (floor) binding
- **Titer**: Present in 70-90%, correlates with disease activity

#### ELISA
- **Anti-BP180 NC16A**: Sensitive and specific
- **Anti-BP230**: Less common
- **Quantitative**: Correlates with disease activity
- **Monitoring**: Useful for treatment response

#### Differential Diagnosis
- **Pemphigus vulgaris**: Flaccid bullae, mucosal involvement, intraepidermal
- **Mucous membrane pemphigoid**: Predominantly mucous membranes, scarring
- **Epidermolysis bullosa acquisita**: Trauma-induced, scarring, dermal side on salt-split
- **Linear IgA disease**: Linear IgA on DIF, often drug-induced
- **Dermatitis herpetiformis**: Grouped vesicles, granular IgA, celiac disease
- **Bullous drug eruption**: Drug history, may be clinical mimicker

### Treatment

#### Topical Therapy (Mild, Localized Disease)
- **Clobetasol propionate 0.05% cream**:
  - Apply to entire body once daily (20-30 g/day)
  - Effective for moderate disease in landmark trial
  - Advantages: Fewer side effects than systemic corticosteroids
  - Taper: Gradually reduce frequency and switch to lower potency
  - Monitoring: Skin atrophy, HPA suppression (if large area)

#### Systemic Corticosteroids (Moderate to Severe)
- **Prednisone**:
  - Dose: 0.5-0.75 mg/kg/day (40-60 mg/day typical)
  - Higher than topical-only disease: More effective for generalized disease
  - Goal: Control blistering within days to weeks
  - Taper: Slow over months (10-20% reduction every 1-2 weeks)
  - Many patients achieve remission off therapy

#### Steroid-Sparing Agents
- **Indications**:
  - High steroid dose required
  - Contraindication to long-term steroids (diabetes, osteoporosis)
  - Relapse with steroid taper
- **Not always necessary**: BP often self-limited

**Options:**

*Doxycycline + Nicotinamide:*
- **Regimen**: Doxycycline 100-200 mg/day + nicotinamide 500 mg TID
- **Mechanism**: Anti-inflammatory (not antibiotic effect)
- **Efficacy**: Mild to moderate disease
- **Advantages**: Safer than other immunosuppressants
- **First-line**: For patients unable to take steroids

*Azathioprine:*
- **Dose**: 1-2.5 mg/kg/day
- **Onset**: 6-12 weeks
- **Monitoring**: CBC, LFTs
- **TPMT testing**: Before initiation

*Mycophenolate Mofetil:*
- **Dose**: 2-3 g/day divided
- **Onset**: 6-12 weeks
- **Monitoring**: CBC

*Methotrexate:*
- **Dose**: 10-25 mg weekly
- **Folic acid**: 1 mg daily
- **Monitoring**: CBC, LFTs, creatinine

*Rituximab:*
- **Indication**: Refractory cases
- **Efficacy**: Effective but expensive
- **Regimen**: Same as pemphigus

*Omalizumab:*
- **Anti-IgE monoclonal antibody**
- **Emerging therapy**: Case reports and series
- **Rationale**: IgE may play role in eosinophil recruitment

*Dupilumab:*
- **IL-4/IL-13 inhibitor** (approved for atopic dermatitis)
- **Emerging**: Case reports showing efficacy
- **Rationale**: Inhibits Th2 response

#### Adjunctive Therapy
- **Antihistamines**: For pruritus (sedating at bedtime)
- **Wound care**: Non-adherent dressings, petroleum-based ointments
- **Treat infections**: Secondary bacterial infection
- **Bone protection**: With chronic steroids
- **Monitor**: Glucose, blood pressure, electrolytes

#### Treatment of Specific Variants
- **Non-bullous/urticarial BP**: May respond to antihistamines and topical steroids alone
- **Localized BP**: Potent topical steroids
- **Mucosal BP**: Systemic therapy usually required

### Disease Course and Prognosis
- **Self-limited**: Most cases remit within 1-5 years
- **Mortality**: Increased in elderly patients
  - Age-matched controls have lower mortality
  - Primarily due to complications (infection, steroid side effects) and comorbidities
- **Remission**: 50-70% achieve remission off therapy within 2-5 years
- **Relapse**: Possible (30-50%), usually milder
- **Associated with mortality**: Extensive disease, advanced age, comorbidities, high steroid doses

### Associations
- **Neurologic diseases**: Dementia, stroke, Parkinson disease, multiple sclerosis
  - Mechanism unclear (neuronal and hemidesmosomal antigens share epitopes?)
- **Malignancy**: Controversial association (some studies positive, others negative)
  - May warrant age-appropriate cancer screening
- **Psoriasis**: Association described
- **Medications**: Drug-induced BP (furosemide, spironolactone, ACE inhibitors, gliptins)

## Mucous Membrane Pemphigoid (MMP)

### Overview
Mucous membrane pemphigoid (formerly cicatricial pemphigoid) is a chronic, autoimmune subepidermal blistering disease predominantly affecting mucous membranes. The hallmark is scarring (fibrosis), particularly of the conjunctivae, leading to blindness if untreated.

### Epidemiology
- **Incidence**: ~1 per million per year
- **Age**: 60-80 years typically
- **Gender**: Female predominance (2:1)

### Pathophysiology
- **Autoantibodies**: Against various basement membrane zone antigens
  - BP180
  - Laminin 332 (formerly laminin 5)
  - BP230
  - Type VII collagen (overlap with EBA)
  - α6β4 integrin
- **Heterogeneous**: Different patients have different target antigens
- **Scarring**: Unique to MMP, mechanism not fully understood
  - Prolonged inflammation
  - Transforming growth factor-β
  - Fibroblast activation

### Clinical Presentation

#### Oral Mucosa (85-90%)
- **Gingiva** (desquamative gingivitis most common presentation)
- **Buccal mucosa, palate, tongue, pharynx**
- **Erosions and ulcers**: Painful, healing with scarring
- **Blisters**: Rare (rupture quickly)

#### Ocular Involvement (60-70%)
- **Conjunctivitis**: Initial symptom
- **Symblepharon**: Adhesions between palpebral and bulbar conjunctiva
- **Ankyloblepharon**: Eyelid margin fusion
- **Forniceal shortening**: Loss of conjunctival fornix depth
- **Entropion/trichiasis**: Inturned eyelid/lashes causing corneal abrasion
- **Dry eyes**: Loss of goblet cells
- **Corneal vascularization and opacification**
- **Blindness**: End-stage complication if untreated

**Stages (Foster staging):**
- **Stage I**: Chronic conjunctivitis
- **Stage II**: Symblepharon and fornix shortening
- **Stage III**: Symblepharon and ankyloblepharon
- **Stage IV**: End-stage dry eye

#### Other Sites
- **Nasal**: Crusting, epistaxis, stenosis
- **Pharynx/larynx**: Hoarseness, dysphagia, stridor, stenosis
- **Esophagus**: Strictures, dysphagia
- **Genital**: Erosions, labial fusion, vaginal stenosis
- **Anal**: Stenosis

#### Cutaneous Involvement (25-30%)
- **Localized**: Head, neck, upper trunk
- **Less common than mucosal**
- **Scarring**: May occur

### Diagnosis
- **Clinical**: Mucosal erosions with scarring
- **Biopsy**: Subepidermal blister with inflammatory infiltrate
- **DIF**: Linear IgG, IgA, or C3 at basement membrane zone (perilesional mucosa)
- **IIF**: Often negative (lower sensitivity than BP)
- **ELISA**: Various antigens depending on case
- **Exclude**: Other cicatrizing conditions (Stevens-Johnson syndrome, lichen planus, graft-versus-host disease)

### Treatment
- **Ophthalmology co-management**: Essential for ocular disease
- **Goal**: Prevent progression and scarring (not reversible)

#### Mild Disease (Oral Only)
- **Topical corticosteroids**: Clobetasol gel, ointment
- **Intralesional corticosteroids**: For localized lesions
- **Dapsone**: 50-150 mg/day
  - Check G6PD before initiating
  - Monitor CBC, methemoglobinemia

#### Moderate to Severe Disease (Ocular, Laryngeal, Esophageal)
- **Aggressive treatment required**: Prevent blindness, airway compromise

**Systemic Corticosteroids:**
- Prednisone 1 mg/kg/day initially
- Taper based on response

**Steroid-Sparing Agents (Start Early):**
- **Mycophenolate mofetil**: 2-3 g/day
  - Considered first-line steroid-sparing by many
- **Azathioprine**: 1-3 mg/kg/day
- **Cyclophosphamide**: 1-2 mg/kg/day
  - Reserved for severe, refractory disease
  - Pulse IV may be better tolerated
  - Significant toxicity (hemorrhagic cystitis, malignancy, infertility)
- **Rituximab**: Refractory cases
- **IVIG**: 2 g/kg monthly

**Ophthalmic Management:**
- **Daily ophthalmology exams initially**: Monitor for progression
- **Topical lubricants**: Artificial tears, ointments
- **Lysis of adhesions**: With glass rod (mechanical disruption of early symblepharon)
- **Surgery**: End-stage (mucous membrane graft, keratoprosthesis)
- **Immunosuppression**: Must be achieved before surgery

#### Adjunctive
- **Oral care**: Soft diet, oral rinses, topical anesthetics
- **Vaginal dilators**: Prevent stenosis

### Prognosis
- **Chronic, progressive**: Without treatment
- **Blindness**: Major complication (25% if untreated ocular disease)
- **Treatment**: Can halt progression but not reverse scarring
- **Monitoring**: Lifelong for ocular disease

## Other Pemphigoid Disorders

### Linear IgA Disease (LAD)
- **DIF**: Linear IgA at basement membrane zone (diagnostic)
- **Clinical**: Chronic bullous disease of childhood (most common) or adults
- **Presentation**: "String of pearls" (vesicles in annular arrangement), tense bullae
- **Mucosa**: Often involved
- **Drugs**: Can be drug-induced (vancomycin most common)
- **Treatment**: Dapsone first-line (very responsive), systemic steroids if needed

### Epidermolysis Bullosa Acquisita (EBA)
- **Antibodies**: Type VII collagen (anchoring fibrils)
- **DIF**: Linear IgG at basement membrane zone
- **Salt-split skin IIF**: Dermal (floor) side binding (vs roof in BP)
- **Clinical**:
  - **Mechanobullous**: Trauma-induced blisters on hands, feet, elbows, knees (most common)
  - **Inflammatory**: Resembles BP
  - **Scarring and milia**: Characteristic
- **Associations**: IBD, SLE, amyloidosis
- **Treatment**: Difficult, refractory
  - Colchicine, dapsone (often ineffective)
  - Rituximab most promising
  - Immunosuppressants

### Pemphigoid Gestationis (Herpes Gestationis)
- **Pregnancy-specific**: Autoimmune blistering disease
- **Antibodies**: Anti-BP180 (NC16A domain)
- **Onset**: Usually second or third trimester, postpartum possible
- **Clinical**: Pruritic urticarial plaques → vesicles and bullae
  - Periumbilical involvement common and characteristic
  - Generalize to trunk, extremities
- **Fetal risk**: Usually minimal (small-for-gestational-age possible, transient neonatal blistering rare)
- **Recurrence**: Subsequent pregnancies (often earlier and more severe), oral contraceptives, menses
- **Treatment**:
  - Topical steroids: Mild cases
  - Systemic steroids: Moderate to severe (safe in pregnancy)
  - Antihistamines: Symptomatic
- **Prognosis**: Resolves postpartum (weeks to months), may flare with subsequent pregnancies

### Dermatitis Herpetiformis (DH)
- **Association**: Celiac disease (gluten-sensitive enteropathy)
- **Antibodies**: IgA anti-tissue transglutaminase, IgA anti-epidermal transglutaminase
- **Clinical**:
  - Intensely pruritic vesicles (often excoriated, hard to find intact)
  - Grouped ("herpetiform") on elbows, knees, buttocks, scalp, back
  - Symmetric distribution
- **DIF**: Granular IgA deposits at tips of dermal papillae (pathognomonic)
- **Associations**:
  - Celiac disease (all patients have gluten sensitivity on biopsy, most asymptomatic GI)
  - Thyroid disease, type 1 diabetes (other autoimmune)
- **Treatment**:
  - **Gluten-free diet**: Definitive treatment (takes months to years)
  - **Dapsone**: Rapid response (48-72 hours), symptomatic
    - Dose: 50-200 mg/day
    - Most patients can discontinue after prolonged gluten-free diet
  - **Sulfapyridine**: Alternative to dapsone
- **Prognosis**: Lifelong gluten sensitivity, excellent control with diet and/or dapsone

## Key Points

- Autoimmune blistering diseases are rare but can be life-threatening; diagnosis requires skin biopsy for histology and direct immunofluorescence
- Pemphigus is characterized by flaccid blisters, positive Nikolsky sign, and intraepidermal split with intercellular IgG on DIF
- Pemphigus vulgaris presents with painful oral erosions followed by cutaneous involvement; treatment requires systemic corticosteroids and steroid-sparing agents
- Rituximab is highly effective for pemphigus and may become first-line therapy, offering durable remissions
- Bullous pemphigoid presents with tense bullae on urticarial plaques, predominantly in elderly; subepidermal split with linear basement membrane IgG on DIF
- Bullous pemphigoid is often self-limited and may be managed with potent topical corticosteroids for localized disease
- Mucous membrane pemphigoid causes scarring of mucous membranes, particularly conjunctivae leading to blindness; requires aggressive treatment
- Paraneoplastic pemphigus has severe mucositis, polymorphic skin lesions, and underlying malignancy; poor prognosis with high mortality
- Dermatitis herpetiformis is associated with celiac disease; treatment includes gluten-free diet and dapsone
- Early diagnosis and treatment of autoimmune blistering diseases prevents complications including scarring, blindness, and death

## References

1. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882-894.
2. Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: Clinical features, diagnosis, and management. Clin Rev Allergy Immunol. 2018;54(1):26-51.
3. Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-1913.
